Project Grant R01CA285925
Award Date
8/6/24
Completion Date
7/31/29
Dollars Obligated
$679K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Milwaukee, WI 53226, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $444,569 to Beth Israel Deaconess Medical Center, Inc. to develop innovative models for hormone receptor positive (HR+) breast cancer using patient-derived organoids and cancer-associated fibroblasts. The goal is to address the lack of representative preclinical models for recurrent and metastatic HR+ breast cancer, which accounts for the majority of breast cancer deaths. The...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $447,340.00 to the University of Miami to investigate epigenetic mechanisms that contribute to endocrine-resistant breast cancer. The study aims to identify vulnerabilities in the COREST-SWI/SNF axis, a key signaling pathway involved in endocrine therapy resistance, with the goal of developing new targeted treatments to improve survival for patients with metastatic,...
This $638,326 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the adaptation and preliminary evaluation of the "ENERGIZE-MBC" cognitive behavioral therapy intervention for fatigue among women with metastatic breast cancer treated with CDK4/6 inhibitors. The key objectives are to: 1) adapt an existing cognitive behavioral therapy for fatigue intervention to the specific needs of women with metastatic breast cancer receiving...
This is a Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), totaling $1,239,420.00 and commencing on September 4, 2024. The award will fund a longitudinal observational study to assess changes in interoception (the brain's processing of internal bodily sensations) along the cancer chemotherapy continuum and its relationship to chemotherapy-induced peripheral neuropathy (CIPN) in 120 patients with breast...
This $684,333 federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports research to evaluate if patient and provider decision support that integrates breast cancer and cardiovascular disease risk assessment can improve the acceptance and uptake of chemoprevention among racially/ethnically diverse women at high risk for breast cancer. The key objectives are to: 1) refine patient-facing and provider-facing decision support tools...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by Emory University to investigate the dynamic regulation of HER2 expression in breast cancer. The project aims to characterize the epigenomic and transcriptional features that enable heterogeneous HER2 expression, including the rapid conversion between HER2-positive and HER2-low states, in order to inform strategies for improving outcomes with HER2-targeted antibody-drug...
This federal Project Grant award of $358,000.00 was provided by the National Cancer Institute (NCI), which administers the Cancer Cause and Prevention Research (CFDA 93.393) program. The grant supports research at Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System Incorporated, to characterize and address non-response in patient-reported outcomes (PRO) data collected as part of routine cancer care. The key objectives are to: 1) Characterize non-response in PRO data...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will provide $163,750 to The Johns Hopkins University to conduct comprehensive preclinical characterization of novel estrogen receptor (ER) mutations that may contribute to endocrine therapy resistance in advanced estrogen receptor-positive (ER+) breast cancer. The award will support two key objectives: 1) assessing the oncogenic potential and downstream signaling of these novel ER...
This Project Grant award for $517,732, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), supports research to investigate how endocrine therapies and radiation therapy (RT) can be combined to decrease brain metastases in breast cancer patients, particularly younger women. The key aims of the 5-year project are to: 1) Determine how endocrine therapies and RT can synergistically promote anti-tumor immune responses in the brain to reduce brain...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Research Manpower (CFDA 93.398) federal grant program, provides $215,740 to Virginia Commonwealth University (VCU) to evaluate the efficacy of the drug elacestrant in pre-clinical models of breast cancer bone metastasis. The overarching goal is to determine if elacestrant, which displays context-dependent agonist and antagonist activity, can extend progression-free survival in these models. The research will...